Abstract | BACKGROUND/AIM: MATERIALS AND METHODS: The CRPC cell line PC3 was used for orthotopic inoculation in male athymic nude mice. The mice were randomly assigned to one of the four treatment groups: Control, docetaxel, desmopressin or combination therapy. Following the last treatment, tumors were excised and measured. Blood samples were processed for CTC analysis. RESULTS:
Docetaxel treatment resulted in a significant reduction in tumor volume compared to control. The combination therapy resulted in even more significant reduction (31.2%) in tumor volume. There was a complete absence of CTCs in the combination group. CONCLUSION:
|
Authors | Roman Bass, Domenica Roberto, Daniel Zongjie Wang, Fernando Pena Cantu, Reza M Mohamadi, Shana O Kelley, Laurence Klotz, Vasundara Venkateswaran |
Journal | Anticancer research
(Anticancer Res)
Vol. 39
Issue 1
Pg. 113-118
(Jan 2019)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 30591447
(Publication Type: Journal Article)
|
Copyright | Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Docetaxel
- Deamino Arginine Vasopressin
|
Topics |
- Animals
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Deamino Arginine Vasopressin
(administration & dosage)
- Docetaxel
(administration & dosage)
- Humans
- Male
- Mice
- Pilot Projects
- Prostatic Neoplasms, Castration-Resistant
(drug therapy, pathology)
- Tumor Burden
- Xenograft Model Antitumor Assays
|